Cat. No.: HY-128932

Cefminox sodium

(Synonyms: MT-141)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.83%
CAS No.: 75498-96-3
Formule: C₁₆H₂₀N₇NaO₇S₃
Masse moléculaire:541.56

Stockage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Cefminox sodium Chemical Structure

CAS No.: 75498-96-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]^[2]

PPARγ

IP Receptor

Bacterial

Voir tous les produits spécifiques à Isoform Antibiotic :

Voir tous les produits spécifiques à Isoform PPAR :

Voir tous les produits spécifiques à Isoform Prostaglandin Receptor :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform mTOR :

In Vitro

Cefminox sodium (Compound MT-141) (0.1-800 μg/mL) is more active against gram-negative and anaerobic bacteria than against gram-positive bacteria^[1].
Cefminox sodium (10-50 μM, 48 h) significantly inhibits the hypoxia-induced cell proliferation dose-dependently in primary pulmonary artery smooth muscle cells (PASMCs) through the enhancement of both IP and PPARγ activities^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

Primary pulmonary artery smooth muscle cells (PASMCs)
Concentration:

10 and 50 μM
Incubation Time:

48 h
Result:

Increased PTEN mRNA levels.
Increased PTEN protein levels in both normoxic and hypoxic conditions.
Inhibited the Akt/mTOR signaling pathway through elevation of PTEN protein levels.
Inhibited cell growth by up-regulation PTEN expression and inhibiting Akt/mTOR signaling in PASMCs under hypoxic conditions.

In Vivo

Cefminox sodium (Compound MT-141) (2-480 mg/kg, s.c., single dose) shows the highest efficacy against strains of Escherichia coli, Klebsiella pneumoniae, Salmonella enteritidis, Proteus morganii, Proteus rettgeri, Proteus vulgaris, Yersinia enterocolitica, Psudomonas cepacia, and Clostridium perfringens in female Slc:ddY mice model^[1].
Cefminox sodium (1-1000 mg/kg, s.c., single dose) gives dose-related serum levels in male Slc:ddY mice^[1].
Cefminox sodium (160-320 mg/kg/day, i.v., single dose) significantly decreases mean pulmonary artery pressure (mPAP) in male SD rats with hypoxia-induced pulmonary hypertension (HPH)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult male Sprague Dawley (SD) rats (150-200 g) with hypoxia-induced pulmonary hypertension (HPH)^[2]
Dosage:

160 and 320 mg/kg/day
Administration:

Intravenous injection (i.v.) in tail, single dose
Result:

Significantly decreased mean pulmonary artery pressure (mPAP) dose-dependently.
Significantly reversed hypoxia-induced pulmonary artery remodeling by decreasing the number of smooth muscle cells.
Increased the expression of PTEN compared with that in the normoxia or hypoxia (no treatment) groups.

Chemical Information

CAS No. 75498-96-3
Appearance Solid
Masse moléculaire 541.56
Formule C₁₆H₂₀N₇NaO₇S₃
Color White to off-white
SMILES

O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@](OC)(NC(CSC[C@@H](N)C(O)=O)=O)C1=O)O[Na]
Synonyms

MT-141
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

Heliyon

Cefminox sodium alleviates the high-fat high-sugar-fed mice's hepatic fatty accumulation via multiple pathways. [Abstract]

2023 Nov 7;9(11):e21973. PMID: 38027801

Solvant et solubilité

In Vitro:

H₂O : 83.33 mg/mL (153.87 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8465 mL

9.2326 mL

18.4652 mL

5 mM

0.3693 mL

1.8465 mL

3.6930 mL

10 mM

0.1847 mL

0.9233 mL

1.8465 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 50 mg/mL (92.33 mM); Clear solution; Need ultrasonic

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Inouye S, et al. In vitro and in vivo antibacterial activities of MT-141, a new semisynthetic cephamycin, compared with those of five cephalosporins. Antimicrob Agents Chemother. 1984 Nov;26(5):722-9. [Content Brief]

[2]. Xia J, et al. Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats. Front Pharmacol. 2018 Feb 23;9:134. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	1.8465 mL	9.2326 mL	18.4652 mL	46.1629 mL
	5 mM	0.3693 mL	1.8465 mL	3.6930 mL	9.2326 mL
	10 mM	0.1847 mL	0.9233 mL	1.8465 mL	4.6163 mL
	15 mM	0.1231 mL	0.6155 mL	1.2310 mL	3.0775 mL
	20 mM	0.0923 mL	0.4616 mL	0.9233 mL	2.3081 mL
	25 mM	0.0739 mL	0.3693 mL	0.7386 mL	1.8465 mL
	30 mM	0.0616 mL	0.3078 mL	0.6155 mL	1.5388 mL
	40 mM	0.0462 mL	0.2308 mL	0.4616 mL	1.1541 mL
	50 mM	0.0369 mL	0.1847 mL	0.3693 mL	0.9233 mL
	60 mM	0.0308 mL	0.1539 mL	0.3078 mL	0.7694 mL
	80 mM	0.0231 mL	0.1154 mL	0.2308 mL	0.5770 mL
	100 mM	0.0185 mL	0.0923 mL	0.1847 mL	0.4616 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Cefminox sodium

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Cefminox sodium

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Cefminox sodium

Voir tous les produits spécifiques à Isoform Antibiotic

Voir tous les produits spécifiques à Isoform PPAR

Voir tous les produits spécifiques à Isoform Prostaglandin Receptor

Voir tous les produits spécifiques à Isoform Akt

Voir tous les produits spécifiques à Isoform mTOR

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Cefminox sodium Related Classifications

HY-128932 Related Classifications